UBS Maintains Neutral on Xylem, Raises Price Target to $138

Benzinga Newsdesk www.benzinga.com Positive 66.5%

Neg 0% Neu 0% Pos 66.5%

UBS analyst Joshua Spector maintains Xylem (NYSE:XYL) with a Neutral and raises the price target from $135 to $138.

Comments

No comments yet. Be the first!